معرفی
Rupert Lanzenberger is a Clinical Professor in Neurosciences at the Medical University of Vienna, where he has served as Director of the NeuroImaging Labs since 2021. He previously held roles as Associate Professor (2012-2021), Assistant Professor with habilitation (2010-2021), and Head of Neuroimaging Labs (2005-present). He chairs the WFSBP Task Force on NeuroImaging and serves on scientific committees including the ERC and Austrian Neuroscience Association.
- MD in Medicine (1998, Medical University of Vienna)
- Habilitation in Neurosciences (2010)
His research focuses on translational molecular neuroimaging using PET/fMRI to study treatment effects in psychiatric and neurological disorders, particularly depression and ADHD. He develops predictive biomarkers and investigates serotonin/norepinephrine transporter dynamics. His work combines functional imaging with psychopharmacology to understand brain plasticity in mental health.
Recent publications show expertise in multimodal imaging techniques (PET, fMRI, ultra-high field MRI) applied to psychiatric disorders, receptor dynamics (5-HT1A, NET, GluN2B), and treatment response modeling. His team's work appears in top journals like Molecular Psychiatry and JAMA Psychiatry.
- Worldwide top 1% Serotonin researcher (2021)
- European Academy of Sciences and Arts member (2019)
- ERC Consolidator Grant panel service
- Editorial board of NeuroImage and International Journal of Neuropsychopharmacology
He supervises research teams and has established an international neuroimaging network with collaborations across >20 countries. The NeuroImaging Labs under his leadership conduct cutting-edge research in psychiatric biomarkers, with expertise in PET, MRI, EEG/TMS, and chemical imaging techniques.
